Vanguard Group Inc. Acquires 69,856 Shares of Nurix Therapeutics, Inc. $NRIX

Vanguard Group Inc. grew its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 1.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,415,122 shares of the company’s stock after purchasing an additional 69,856 shares during the period. Vanguard Group Inc. owned approximately 5.79% of Nurix Therapeutics worth $52,452,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. RA Capital Management L.P. acquired a new position in Nurix Therapeutics during the 4th quarter worth about $25,120,000. Soleus Capital Management L.P. raised its position in shares of Nurix Therapeutics by 97.3% in the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock worth $39,617,000 after acquiring an additional 1,036,999 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $16,447,000. Boxer Capital Management LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $10,608,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Nurix Therapeutics in the 4th quarter valued at about $4,321,000.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. HC Wainwright decreased their target price on Nurix Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, July 14th. Stephens reissued an “overweight” rating and set a $30.00 price objective on shares of Nurix Therapeutics in a report on Thursday, July 10th. UBS Group decreased their price objective on Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, July 10th. Morgan Stanley set a $16.00 price objective on Nurix Therapeutics and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.87.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $9.67 on Tuesday. The company has a market cap of $739.26 million, a P/E ratio of -3.70 and a beta of 2.14. The stock’s fifty day moving average price is $11.36 and its two-hundred day moving average price is $11.95. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.27. The firm had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total value of $51,739.08. Following the transaction, the insider owned 69,023 shares of the company’s stock, valued at $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 5,402 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer directly owned 35,512 shares in the company, valued at approximately $391,697.36. This represents a 13.20% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,014 shares of company stock worth $163,014. Insiders own 7.40% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.